What we are studying
This study has two study groups (Arm 1 and Arm 2). Patients in Arm 1 will take 3 placebo tablets by mouth. Patients in Arm 2 will take 3 regorafenib tablets by mouth. The regorafenib and placebo tablets look the same. Neither the study participant, their doctor, nor the study team will know whether the study participant is taking placebo or regorafenib.
Study participants will be randomized to either Arm 1 or Arm 2. Randomized means that a computer will, by chance, assign them to either Arm 1 or Arm 2 of the study (like flipping a coin). Half of the patients joining this study will be assigned to Arm 1; the other half of patients will be assigned to Arm 2. This is done because no one knows if taking regorafenib after adjuvant chemotherapy is better or worse than no further therapy.
Parking will be validated for all study related visits.